{
  "id": 6737,
  "url": "https://nnemf.org/research/6737-amplitude-modulated-electromagnetic-fields-for-the-treatment-of",
  "title": "Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach",
  "authors": [
    "Alexandre Barbault",
    "Frederico P Costa",
    "Brad Bottger",
    "Reginald F Munden",
    "Fin Bomholt",
    "Niels Kuster",
    "Boris Pasche"
  ],
  "journal": "J Exp Clin Cancer Res",
  "year": "2009",
  "doi": "10.1186/1756-9966-28-51",
  "pmid": "19366446",
  "abstract": "Purpose: Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer. Patients and methods: We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options. Results: We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57-92%) were specific for a single tumor type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4 toxicities. Thirteen patients were evaluable for response. One patient with hormone-refractory breast cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. One patient with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5 months. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1 months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to liver). Conclusion: Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer. Trial registration: clinicaltrials.gov identifier NCT00805337.",
  "effect": "mixed",
  "evidence": "very_low",
  "extraction": {
    "studyType": "other",
    "studyTypeLabel": "Other",
    "effectDirection": "mixed",
    "evidenceLabel": "Very low",
    "population": "Patients with various types of cancer; compassionate treatment in patients with advanced cancer and limited therapeutic options",
    "sampleSize": "163",
    "exposure": "ELF <1 MHz",
    "confidencePct": "74",
    "peerReviewed": "yes",
    "mainFindings": "Using a noninvasive biofeedback method, 1524 frequencies (0.1 Hz to 114 kHz) were identified in 163 cancer patients, with most frequencies (57–92%) reported as specific to a single tumor type. Compassionate treatment was offered to 28 patients; among 13 evaluable for response, 1 complete response (11 months), 1 partial response (13.5 months), and 4 cases of stable disease (4.0 to >34.1 months) were reported. Toxicity was limited to grade 1 fatigue in three patients, with no grade 2–4 toxicities reported.",
    "outcomes": [
      "Identification of tumor-specific frequencies",
      "Adverse events/toxicity (NCI grading)",
      "Tumor response (complete response",
      "partial response",
      "stable disease)",
      "Feasibility/tolerability of administering tumor-specific frequencies"
    ],
    "limitations": [
      "Noninvasive biofeedback method used to identify frequencies",
      "details not provided in abstract",
      "Compassionate-use treatment without stated control group",
      "Only 13/28 treated patients were evaluable for response",
      "Heterogeneous cancer types and metastatic sites",
      "Duration of exposure/treatment regimen not specified in abstract",
      "No SAR or field strength/exposure metrics reported in abstract"
    ],
    "keywords": [
      "amplitude-modulated electromagnetic fields",
      "tumor-specific frequencies",
      "biofeedback",
      "compassionate treatment",
      "advanced cancer",
      "0.1 Hz",
      "114 kHz",
      "feasibility",
      "toxicity",
      "clinical response"
    ],
    "hubs": [],
    "raw": "{\n  \"study_type\": \"other\",\n  \"exposure\": {\n    \"band\": \"ELF\",\n    \"source\": \"therapeutic device/systemic delivery (amplitude-modulated electromagnetic fields)\",\n    \"frequency_mhz\": null,\n    \"sar_wkg\": null,\n    \"duration\": null\n  },\n  \"population\": \"Patients with various types of cancer; compassionate treatment in patients with advanced cancer and limited therapeutic options\",\n  \"sample_size\": 163,\n  \"outcomes\": [\n    \"Identification of tumor-specific frequencies\",\n    \"Adverse events/toxicity (NCI grading)\",\n    \"Tumor response (complete response, partial response, stable disease)\",\n    \"Feasibility/tolerability of administering tumor-specific frequencies\"\n  ],\n  \"main_findings\": \"Using a noninvasive biofeedback method, 1524 frequencies (0.1 Hz to 114 kHz) were identified in 163 cancer patients, with most frequencies (57–92%) reported as specific to a single tumor type. Compassionate treatment was offered to 28 patients; among 13 evaluable for response, 1 complete response (11 months), 1 partial response (13.5 months), and 4 cases of stable disease (4.0 to >34.1 months) were reported. Toxicity was limited to grade 1 fatigue in three patients, with no grade 2–4 toxicities reported.\",\n  \"effect_direction\": \"mixed\",\n  \"limitations\": [\n    \"Noninvasive biofeedback method used to identify frequencies; details not provided in abstract\",\n    \"Compassionate-use treatment without stated control group\",\n    \"Only 13/28 treated patients were evaluable for response\",\n    \"Heterogeneous cancer types and metastatic sites\",\n    \"Duration of exposure/treatment regimen not specified in abstract\",\n    \"No SAR or field strength/exposure metrics reported in abstract\"\n  ],\n  \"evidence_strength\": \"very_low\",\n  \"confidence\": 0.74,\n  \"peer_reviewed_likely\": \"yes\",\n  \"keywords\": [\n    \"amplitude-modulated electromagnetic fields\",\n    \"tumor-specific frequencies\",\n    \"biofeedback\",\n    \"compassionate treatment\",\n    \"advanced cancer\",\n    \"0.1 Hz\",\n    \"114 kHz\",\n    \"feasibility\",\n    \"toxicity\",\n    \"clinical response\"\n  ],\n  \"suggested_hubs\": []\n}"
  },
  "synthesis": null,
  "synthesisStatus": "pending",
  "originalHref": "https://pubmed.ncbi.nlm.nih.gov/19366446/",
  "sourceUrl": "https://rfsafe.org/mel/paper.php?id=6737",
  "updated": "2026-02-25 06:37:36"
}